Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Keywords: RECEPTOR ; tumor ; carcinoma ; CELL ; Germany ; LUNG ; THERAPY ; CT ; DIAGNOSIS ; LUNG-CANCER ; DISEASE ; HISTORY ; liver ; PATIENT ; primary ; prognosis ; tumour ; LYMPH-NODES ; 5-FLUOROURACIL ; NO ; NEOPLASIA ; MALIGNANCIES ; METASTASIS ; metastases ; chemotherapy ; INVOLVEMENT ; SCINTIGRAPHY ; LIVER METASTASES ; SOMATOSTATIN ; POOR-PROGNOSIS ; pancreatic carcinoma ; ETOPOSIDE ; CELL CARCINOMA ; MALIGNANCY ; ENDOCRINE ; EXTRAPULMONARY ; GEMCITABINE ; NODES ; OF-THE-LITERATURE ; pancreas ; review ; small cell carcinoma ; somatostatin-analogue ; UNDIFFERENTIATED CARCINOMA
    Abstract: Small cell carcinoma (SCC) of the pancreas is a rare malignancy with an extremely poor prognosis. We present the case of a 74-year-old man with a 2-month history of upper abdominal discomfort who was diagnosed with SCC of the pancreas tail, involvement of peripancreatic and mesenteric lymph nodes and multiple liver metastases ( extended disease). A CT scan and a positive somatostatin receptor scintigraphy showed no evidence of a primary lung tumour. The diagnosis of a SCC was confirmed by biopsy. Local tumour control could be achieved by gemcitabine once a week and a long-acting somatostatin analogue once a month, but liver metastasis showed progress. Thus, 5-fluorouracil on a weekly basis was started. The patient died 8 months after diagnosis and had not been hospitalised in the meantime. Copyright (C) 2004 S. Karger AG, Basel and IAP
    Type of Publication: Journal article published
    PubMed ID: 15334003
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Keywords: CANCER ; SURVIVAL ; tumor ; Germany ; THERAPY ; TOXICITY ; FOLLOW-UP ; COHORT ; DRUG ; MONOCLONAL-ANTIBODY ; PATIENT ; murine ; colon ; treatment ; antibodies ; antibody ; GLYCOPROTEIN ; TRIAL ; COLON-CANCER ; MONOCLONAL-ANTIBODIES ; FLUOROURACIL ; folinic acid ; ONCOLOGY ; colon cancer ; overall survival ; ADJUVANT THERAPY ; SWITZERLAND ; methods ; PHASE ; monoclonal antibodies ; monoclonal antibody ; edrecolomab ; MONOCLONAL-ANTIBODY THERAPY ; stage II
    Abstract: Background: In a phase III study recruiting patients with stage II colon cancer the effect of adjuvant therapy with edrecolomab, a murine monoclonal antibody to the cell-surface glycoprotein 17-1A, was compared to observation alone. Patients and Methods: From January 1997 until July 2000 a total of 377 patients were postoperatively stratified according to tumor stage (T3 vs. T4) and center, and randomly allocated to either treatment with edrecolomab ( cohort A, n = 183) or observation ( cohort B, n = 194). Patients in cohort A received a total of 900 mg edrecolomab. The study was terminated prematurely because of discontinuation of drug supply in Germany. Results: 305 patients were eligible for the primary endpoint of overall survival and 282 patients for disease-free survival. After a median follow-up of 42 months overall survival and disease-free survival were not significantly different. Toxicity was mild. Conclusions: In the present study, postoperative adjuvant treatment with edrecolomab in patients with resected stage II colon cancer did not improve overall or disease-free survival
    Type of Publication: Journal article published
    PubMed ID: 15933423
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    Electronic Resource
    Electronic Resource
    Springer
    Der Onkologe 5 (1999), S. 30-34 
    ISSN: 1433-0415
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Die Etablierung von adjuvanten Therapieverfahren bei kolorektalen Karzinomen seit Anfang der 90er Jahre ist das Ergebnis einer intensiven klinischen Forschung. Die uns heute vorliegenden Ergebnisse zahlreicher prospektiv randomisierter, multizentrischer Therapiestudien aus westlichen Ländern belegen eindrucksvoll, daß mit Hilfe postoperativer adjuvanter Therapien bei Mittelstadien kolorektaler Karzinome eine beträchtliche Verbesserung der Gesamtprognose erzielt werden kann.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 4
    ISSN: 1432-0584
    Keywords: Erythroblast proliferation ; Chronic renal failure ; Cytophotometry and autoradiography
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Das Proliferationsverhalten der Erythroblasten im Knochenmark von Patienten mit chronischem Nierenversagen wurde mit Hilfe der kombinierten zytophotometrischen DNA-Messung und autoradiographischen in vitro3H-TdR-Markierung untersucht. In den meisten Fällen wurde eine deutliche Verminderung der3H-TdR-Markierung gefunden. Dabei war der Anteil unmarkierter diploider (G0 + G1) und tetraploider Zellen erhöht. Die Ergebnisse lassen sowohl eine gestörte Induktion der DNA-Synthese der Ruhezellen als auch eine Blockierung der Zellen in G2 vermuten, die für die ineffektive Zellproduktion bei dieser Erkrankung ursächlich sind.
    Notes: Summary Proliferation of bone marrow erythroblasts in patients with chronic renal disease was studied by combined application of cytophotometric measurement of the DNA content and3H-TdR labeling in vitro. A striking decrease of3H-TdR labeling was found in most of the cases. The proportion of diploid (G0 + G1) as well as of tetraploid unlabeled cells (G2) was increased. The data suggest a disturbed induction of DNA synthesis of resting cells as well as an arrest of cells in G2 being responsable for ineffective cell production in this disease.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 5
    ISSN: 1432-0584
    Keywords: Knochenmark ; Megakaryozytäre Vorläuferzellen ; Megakaryopoese ; Immunfluoreszenz ; Antithrombozytenserum ; Zytophotometrie ; Bone marrow ; Megakaryocytic precursor cells ; Megakaryopoiesis ; Immunofluorescence ; Antithrombocytic serum ; Cytophotometry
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary The DNA-content of fluoresceine-labeled platelet antigen containing cells of mouse bone marrow was measured. For immunofluorescence highly specific anti-mouse-platelet-serum and fluoresceine-conjugated antigammaglobuline was used, applying the “sandwich” technique. Three hundred panoptically identifiable megakaryocytes served as control group. The DNA-polyploidization pattern of megakaryocytes and immunofluorescence positive cells was almost identical. However, among the immunofluorescence positive cells a considerable amount of cells showed DNA-values lower than 4c, whereas the megakaryocytes of the Pappenheim stained smears revealed no DNA values lower than 4c. The percentages of diploid and tetraploid cells, respectively, was 6 and 7% compared with 0 and 1% of panoptically identifiable megakaryocytes. The results suggest that young megakaryocytic cells with diploid and tetraploid DNA-values can be detected by immunofluorescence technique, indicating that the flow from the uncommited to the committed megakaryocytic precursor cell appears at this early stage of megakaryocyte production.
    Notes: Zusammenfassung Es wurde der DNA-Gehalt von fluoreszeinmarkierten, Thrombozytenantigen enthaltenden Zellen im Knochenmark der Maus untersucht. Die Immunfluoreszenz wurde mit hochspezifischem Anti-Mäuse-Thrombozyten-Serum nach der „sandwich“-Methode mit fluoreszeinkonjugiertem Antigammaglobulin durchgeführt. Als Vergleich dienten 300 nach panoptischen Kriterien differenzierbare Megakaryozyten. Das DNA-Verteilungsmuster der Megakaryozyten und der immunfluoreszenzpositiven Zellen war weitgehend identisch. Allerdings wiesen die immunofluoreszenzpositiven Zellen DNA-Werte auch unterhalb 4c auf, während die im Pappenheim-Präparat differenzierbaren Megakaryozyten keine DNA-Werte in diesem Bereich erkennen ließen. Der Anteil diploder bzw. tetraploider immunfluoreszenzpositiver Zellen betrug 6 bzw. 7% im Vergleich zu 0 bzw. 1% bei den panoptisch differenzierbaren Megakaryozyten. Die Ergebnisse lassen den Schluß zu, daß mit Hilfe der Immunfluoreszenz megakaryozytäre Zellen mit diploidem bzw. tetraploidem DNA-Gehalt nachgewiesen werden können. Dies deutet darauf hin, daß der Einstrom der Zellen aus dem undeterminierten Vorläuferzellkompartment in das determinierte Kompartment bereits auf dieser frühen Stufe der Megakaryozytenproduktion stattfindet.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 6
    ISSN: 1432-0584
    Keywords: Key words De novo AML ; Adults ; HD-Ara-C/DNR consolidation
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract  A total of 149 consecutive de novo AML patients aged 50 years or less (median age = 37 years) were enrolled in this prospective multicenter trial initiated in May 1985. All patients received the same induction and early consolidation therapy with daunorubicin (DNR), cytosine arabinoside (Ara-C), and etoposide (DAV). High-dose Ara-C/DNR therapy included Ara-C at 3 g/m2, in 12 doses (HD-Ara-C/DNR I) and eight doses (HD-Ara-C/DNR II), followed by DNR 30 mg/m2 for 3 days. A complete remission (CR) was achieved in 104 (70%) patients; 61 complete responders received at least one cycle with HD-Ara-C/DNR. If those patients who were transplanted in first CR (n = 26), were not considered, the median relapse-free-survival (MRFS) of the remaining 78 patients was 15 months, with a probability of relapse-free survival (RFS) at 116 months of 30% (95% CI, 20–40%) after a median follow-up of 95 months. The MRFS of the HD-Ara-C/DNR consolidated patients was 25 months, with a probability of RFS at 116 months of 37% (95% CI, 24–50%). If all patients who were transplanted (n = 44) were not considered, the median survival time (MST) was 18 months with a probability of being alive at 118 months of 24% (95% CI, 16–33%). MST of the HD-Ara-C/DNR consolidated patients was 58 months with a survival probability of 46% (95% CI, 31–60%) at 118 months. Prognostic factor analysis did not reveal any significant influence of age, sex, FAB subtype, white blood cell count, hemoglobin level, thrombocyte count, LDH, or response to the first induction course on RFS of the HD-Ara-C/DNR consolidated patients. In summary, HD-Ara-C/DNR consolidation can improve the long-term outcome of a subgroup of de novo AML patients. Further improvement of the outcome seems to depend on the identification of patients with an inferior outcome under that strategy who might benefit from alternative treatment strategies.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 7
    ISSN: 1432-0584
    Keywords: De novo AML ; Adults ; HD-Ara-C/DNR consolidation
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract A total of 149 consecutive de novo AML patients aged 50 years or less (median age = 37 years) were enrolled in this prospective multicenter trial initiated in May 1985. All patients received the same induction and early consolidation therapy with daunorubicin (DNR), cytosine arabinoside (Ara-C), and etoposide (DAV). High-dose Ara-C/DNR therapy included Ara-C at 3 g/m2, in 12 doses (HD-Ara-C/DNR I) and eight doses (HD-Ara-C/DNR II), followed by DNR 30 mg/m2 for 3 days. A complete remission (CR) was achieved in 104 (70%) patients; 61 complete responders received at least one cycle with HD-Ara-C/DNR. If those patients who were transplanted in first CR (n=26), were not considered, the median relapsefree-survival (MRFS) of the remaining 78 patients was 15 months, with a probability of relapse-free survival (RFS) at 116 months of 30% (95% CI, 20–40%) after a median follow-up of 95 months. The MRFS of the HD-Ara-C/DNR consolidated patients was 25 months, with a probability of RFS at 116 months of 37% (95% CI, 24–50%). If all patients who were transplanted (n=44) were not considered, the median survival time (MST) was 18 months with a probability of being alive at 118 months of 24% (95% CI, 16–33%). MST of the HD-Ara-C/DNR consolidated patients was 58 months with a survival probability of 46% (95% CI, 31–60%) at 118 months. Prognostic factor analysis did not reveal any significant influence of age, sex, FAB subtype, white blood cell count, hemoglobin level, thrombocyte count, LDH, or response to the first induction course on RFS of the HD-Ara-C/DNR consolidated patients. In summary, HD-Ara-C/DNR consolidation can improve the long-term outcome of a subgroup of de novo AML patients. Further improvement of the outcome seems to depend on the identification of patients with an inferior outcome under that strategy who might benefit from alternative treatment strategies.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 8
    ISSN: 1432-0584
    Keywords: Bone marrow ; Megakarocyte precursor cells ; Immunofluorescence ; Antiplatelet antibody ; Cytophotometry
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary A sequential preparation method is described which allows immunological identification, morphological characterization, cytophotometric determination of relative DNA content of the megakaryocyte lineage as well as quantitation of megakaryocyte precursors in human bone marrow aspirates. We compared several monoclonal (anti-GP IIIa and HD 19) and polyclonal (A 225, RAHPS) antiplatelet antibodies for immunoflurescent staining. Among the identified cells, a small number of cells showing a diploid and tetraploid DNA content were found which must be regarded as promegakaryoblasts, representing 2.5–4.7% of all megakaryocytes. The heterogenous morphology of these precursors in panoptically stained smears is described.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 9
    ISSN: 1432-0584
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 10
    ISSN: 1432-0711
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...